Currently, major pharmaceutical companies are focusing on investigating more targeted approaches to cancer therapy. Cancer R & D is rapidly migrating from traditional cytotoxic chemotherapies toward higher specificity immunological and biological approaches that target unique biochemical receptors and signaling pathways. For 2002-2004, market growth in cancer therapeutics will be dominated by novel agents, such as anti-angiogenics, monoclonal antibodies, topoisomerase inhibitors, and aromatase inhibitors. Any company not heavily invested in these areas will fail to achieve a strong market presence. These new drugs will be more cancer- and patient-specific and will have the potential for slowing cancer growth and inhibiting disease progression, with fewer adverse effects on the patient.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Outlook for Cancer Therapeutics: An Analysis of Key Competitor Pipelines, a DR Reports publication from Decision Resources, Inc., profiles the emerging therapies in ten leading R&D pipelines. This 142-page report focuses on the four most common types of cancer: lung, colorectal, breast, and prostate. It provides an excellent overview of disease pathophysiology, staging, diagnosis, standard of care, risk factors, and current therapies.

Companies profiled include: Bristol-Myers Squibb, AstraZeneca, Roche, Genentech, Aventis, Pharmacia, Sugen, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, and Ilex Oncology. The report highlights these companies':

  -- Marketed and development-stage drugs   -- Patent position   -- Financial outlook   -- Future promise  

Outlook for Cancer Therapeutics: An Analysis of Key Competitor Pipelines is currently available for $5,250 in print and electronic format.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

   Contact    Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or    tdaley@dresources.com.    In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347    (fax), or fbidart@decisionresources.be.    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel),    +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp. 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87136161

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, Inc., +1-781-296-2636, or
tdaley@dresources.com

New Report From Decision Resources Evaluates Emerging Therapies to Treat Pancreatic Cancer

View Now